RxDoctor Payments Data

Robert Shapiro

Neurology · Burlington, VTNPI 1912914318

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $65,476 of the $90,266 with a category attached, or 72.5%. 6 manufacturers reported payments, led by Lilly USA, LLC at 52.9% of the total. Among neurology clinicians in VT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$90,266in general payments, 2019–2025

Across 87 payments — averaging $1037.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$48K
  • Eli Lilly$28K
  • Axsome Therapeutics, Inc.$6K
  • Pfizer$5K
  • Amneal Pharmaceuticals LLC$3K
  • AbbVie$263

What the payments were for

  • Consulting fees$65,47673%
  • Speaking & faculty fees$5,8006%
  • Travel & lodging$16,24518%
  • Food & beverage$1,7452%
  • Education$1,0001%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC57$47,737
Eli Lilly22$28,408
Axsome Therapeutics, Inc.3$5,908
Pfizer1$5,000
Amneal Pharmaceuticals LLC3$2,950
AbbVie1$263

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,266 in reported general payments places this provider in the 90th percentile of 41 neurology providers in Vermont.

See all neurology providers in Vermont

Medicare billing

Part B allowed, 2024
$9,493
Medicare patients
46
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate43$77,684
QuliptaAtogepant30$67,224
Emgality PenGalcanezumab-Gnlm44$50,209
Ajovy AutoinjectorFremanezumab-Vfrm38$47,194
Aimovig AutoinjectorErenumab-Aooe20$41,976
Eletriptan HbrEletriptan Hydrobromide12$1,151
RizatriptanRizatriptan Benzoate57$1,089
Sumatriptan Succinate49$818
Topiramate27$240
Metoprolol Succinate12$218
Gabapentin14$165
Amlodipine Besylate14$63
Tizanidine Hcl11$51

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$5,000$77,68443 claims
AbbVieQulipta$263$67,22430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 neurology providers in Vermont.

Other neurology in Burlington

See the full list for Vermont

Where these figures come from

Is this you, or does something look wrong? →